Outcome of Anthracycline versus Taxane Based Regimens on Different Metastatic Sites in Breast Cancer | ||||
| SECI Oncology Journal | ||||
| Volume 12, Issue 2, April 2024, Page 206-214 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background: Breast cancer holds a wide spectrum of heterogeneity in terms of gene expression, immunophenotypes, treatment response and clinical outcomes. Metastatic breast cancer is an incurable disease and the main aims of treatment are survival prolongation and improvement quality of life. Median survival is established by tumor biology, therapy response, patient tolerance to treatment and comorbid diseases. The overall median survival for each subgroup is approximately 2.5 years. Several studies suggested that the regimens based on anthracycline are better than regimens based on taxanes in the progression time. Our study aims to evaluate comparison between anthracycline versus taxanes containing regimens in treatment of metastatic breast cancer patients. Material and Method: This is a retrospective cohort study of 225 cases of metastatic breast cancer at Medical Oncology Department of South Egypt Cancer Institute, Assiut University in the timeline between January 2013 to December 2018. Patients were selected to be pathologically confirmed metastatic disease at time of presentation or recurrence after surgery with different pathological subtypes in female patients to assess comparison between anthracycline versus taxanes containing regimen in treatment of metastatic breast cancer patients and their effect on different metastatic sites and on survival. Result: Clinicopathological criteria was almost balanced between the two groups including age, menopausal status, tumor size, nodal status, distant metastasis, tumor grade, histo-pathological criteria, hormonal status and site of metastasis. The patients with liver metastases shown more significant response with anthracycline based regimen than with taxane based regimen (80.0% vs 35.7% P value <0.001) but the response rate of other metastatic sites in both groups were nearly comparable. The patients who received taxane based regimen shown higher OS than the patients who received anthracycline based regimen (74.5 ± 5.2% vs 54.9 ± 6.5% P value 0.015) but no difference appeared in PFS on both groups. Conclusion: Anthracycline based regimen shows significant improvement in response rate in patients with liver metastases in comparison to taxane based regimen while the patients who received taxane based regimen show more significant OS but no difference in PFS in both groups. | ||||
| Keywords | ||||
| metastatic breast cancer; anthracycline; taxanes; metastatic sites; RR; PFS; OS | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 66 |
||||
